{"protocolSection": {"identificationModule": {"nctId": "NCT00702325", "orgStudyIdInfo": {"id": "D589BL00003"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Phase4/Symbicort\u00ae Versus Pulmicort Flexhaler\u00ae in African Americans", "officialTitle": "A 12-wk, Rand., Double-blind, Double Dummy, Multi-ctr., Phase IV Study Comparing Efficacy and Safety of SYMBICORT\u00ae pMDI 160/4.5 ug x 2 Actuations Twice Daily Versus Pulmicort\u00ae (Budesonide Inhalation Powder DPI) 180 ug x 2 Inhalations Twice Daily, in Adult and Adolescent African American Subjects With Asthma", "acronym": "Titan"}, "statusModule": {"statusVerifiedDate": "2012-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-06"}, "primaryCompletionDateStruct": {"date": "2009-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-06-19", "studyFirstSubmitQcDate": "2008-06-19", "studyFirstPostDateStruct": {"date": "2008-06-20", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-09-20", "resultsFirstSubmitQcDate": "2012-10-10", "resultsFirstPostDateStruct": {"date": "2012-11-09", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-10-10", "lastUpdatePostDateStruct": {"date": "2012-11-09", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "To compare the efficacy of SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2 actuations twice daily (bid) to that of budesonide inhalation powder DPI 180 \u03bcg x 2 inhalations bid, in African American(self-reported) subjects with inhaled corticosteroid (ICS) dependent asthma."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 311, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Budesonide / formoterol fumarate (SYMBICORT)"]}, {"label": "2", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Budesonide"]}], "interventions": [{"type": "DRUG", "name": "Budesonide / formoterol fumarate (SYMBICORT)", "description": "160/4.5 \u03bcg x 2 actuations twice daily (bid)", "armGroupLabels": ["1"], "otherNames": ["SYMBICORT"]}, {"type": "DRUG", "name": "Budesonide", "description": "inhalation powder 180 \u03bcg x 2 inhalations bid (PULMICORT)", "armGroupLabels": ["2"], "otherNames": ["PULMICORT"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) Averaged Over Treatment Period", "description": "Mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "timeFrame": "Baseline to 12 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Morning Peak Expiratory Flow (AM PEF) Averaged Over the Treatment Period", "description": "Mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Change From Baseline in Evening Peak Expiratory Flow (PM PEF) Averaged Over the Treatment Period", "description": "Mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Change From Baseline in Pre-dose Forced Vital Capacity (FVC) Averaged Over the Treatment Period", "description": "Mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Change From Baseline in Pre-dose Forced Expiratory Flow (FEF 25-75%) Averaged Over the Treatment Period", "description": "Mean change of the FEF (25-75%) value at the baseline (Visit 3) compared to average value of the FEF (25-75%) recorded at visits during treatment period (to week 12). The mean change was calculated.", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Number of First Predefined Asthma Events by Inhaled Corticosteroid (ICS) Dose at Entry", "description": "Total number of participants with any first predefined asthma event (decrease in FEV1 \u2265 20%,or to \\<40% of predicted normal value,12 puffs of albuterol pMDI per day on 3 or more days, decrease in morning PEF \u2265 20% on 3 or more days, use of rescue medication for 2 or more nights, emergency treatment, hospitalization, use of other asthma medication)", "timeFrame": "12 weeks"}, {"measure": "Number of Withdrawals Due to a Predefined Asthma Event", "description": "Total number of participants who withdrew due to a predefined asthma event (decrease in FEV1 \u2265 20%,or to \\<40% of predicted normal value,12 puffs of albuterol pMDI per day on 3 or more days, decrease in morning PEF \u2265 20% on 3 or more days, use of rescue medication for 2 or more nights, emergency treatment, hospitalization, use of other asthma meds)", "timeFrame": "12 weeks"}, {"measure": "Change From Baseline in Total Average Daily Asthma Symptom Score Averaged Over the Treatment Period", "description": "Diary assessment of total asthma symptoms score (treatment average) by Inhaled Corticosteroid (ICS) dose at entry. Asthma symptoms are cough, wheeze and shortness of breath. Each symptom is usually rated from 0-3: 0-no symptoms, 1-mild, 2-moderate and 3-severe. Change from baseline (Visit 3) mean value to average value recorded at visits during treatment period", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Change From Baseline in Nighttime Asthma Symptom Score Averaged Over the Treatment Period", "description": "Diary assessment of nighttime asthma symptoms score (treatment average) by ICS dose at entry. Asthma symptoms are cough, wheeze and shortness of breath. Each symptom is usually rated from 0-3: 0-no symptoms, 1-mild, 2-moderate and 3-severe. Change from baseline (Visit 3) mean value to average value recorded at visits during treatment period; full analysis set (FAS)", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Change From Baseline in Daytime Asthma Symptom Score Averaged Over the Treatment Period", "description": "Diary assessment of daytime asthma symptoms score (treatment average) by ICS dose at entry. Asthma symptoms are cough, wheeze and shortness of breath. Each symptom is usually rated from 0-3: 0-no symptoms, 1-mild, 2-moderate and 3-severe. Change from baseline (Visit 3) mean value to average value recorded at visits during treatment period; full analysis set (FAS)", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Change From Baseline in Awakening-free Nights Averaged Over the Treatment Period", "description": "Diary assessment of number of nights free from awakenings due to asthma; mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Change From Baseline to the Average in Total Rescue Medication Use Averaged Over the Treatment Period", "description": "Diary assessment of total daily puffs of rescue medication used for asthma symptoms relief; mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Change From Baseline to the Average in Nighttime Rescue Medication Use Averaged Over the Treatment Period", "description": "Diary assessment of total nighttime puffs of rescue medication used for asthma symptoms relief; mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Change From Baseline to the Average in Daytime Medication Use Averaged Over the Treatment Period", "description": "Diary assessment of total daytime puffs of rescue medication used for asthma symptoms relief; mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Change From Baseline to the Average in Rescue Medication-free Days Averaged Over the Treatment Period", "description": "Diary assessment of total (percent) days free from rescue medication use for asthma symptoms relief; mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Change From Baseline in Asthma Symptom-free Days Averaged Over the Treatment Period", "description": "Diary assessment of number (percent) of days free from asthma symptoms by ICS dose at entry; mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Change From Baseline to the Average for Asthma-control Days Averaged Over the Treatment Period", "description": "Diary assessment of number (percent) of asthma-control days (defined as days that were free of symptoms and nighttime and daytime rescue medication use); mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Perception of Onset of Medication Effect at Last Week of Treatment Assessed by Number of Participants Who Agreed With Item 2 on the Onset of Effect Questionnaire (OEQ)", "description": "Diary assessment of participants age 12 years and older and 18 years and older who agreed with OEQ Item 2 at last week of treatment - During the past week, you could feel your medication begin to work right away", "timeFrame": "12 week"}, {"measure": "Change From Baseline to End of Treatment in Overall Score on the Asthma Quality of Life Questionnaire-Standardized (AQLQ[S])", "description": "Mean change in overall score at end of treatment for participants age 17 years and older (scores ranged from 1 to 7, with higher scores indicating better quality of life); mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Proportion of Participants Who Reported on the Asthma Control Test (ACT) That Their Asthma Was Controlled at the Last Week of Treatment", "description": "There are 5 questions in the survey, and each question has 5 responses (total score for each question can range from 1 to 5). To score the survey, responses to the 5 questions are added to yield a total score that ranges from 5 (poor control of asthma control) to 25 (complete control of asthma). Score of 20 or higher was indicative of well-controlled asthma.", "timeFrame": "12 weeks"}, {"measure": "Change From Baseline to Last Week of Treatment in Scores on the Asthma Impact Survey (AIS)", "description": "There are 6 questions in the survey, and each question has 5 responses (total score for each question can range from 6 to 13). Responses to the 6 questions were added to yield a total score that ranged from 36 to 78. Scoring is based on a norm-based method. Higher AIS scores indicated more asthma impact and poorer quality of life; mean change from baseline (Visit 3) value to average value recorded at visits during treatment period.", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Perception of Onset of Medication Effect at Last Week of Treatment Assessed by Number of Participants Who Agreed With Item 5 on the Onset of Effect Questionnaire (OEQ)", "description": "Diary assessment of participants age 12 years and older and 18 years and older who agreed with OEQ Item 5 at last week of treatment - During the past week, you were satisfied with how quickly you felt your study medication began to work.", "timeFrame": "12 week"}, {"measure": "Perception of Onset of Medication Effect at First Week of Treatment Assessed by Number of Participants Who Agreed With Item 2 on the Onset of Effect Questionnaire (OEQ)", "description": "Diary assessment of participants age 12 years and older and 18 years and older who agreed with OEQ Item 2 at first week of treatment - During the past week, you could feel your medication begin to work right away", "timeFrame": "1 week"}, {"measure": "Perception of Onset of Medication Effect at First Week of Treatment Assessed by Number of Participants Who Agreed With Item 5 on the Onset of Effect Questionnaire (OEQ)", "description": "Diary assessment of participants age 12 years and older and 18 years and older who agreed with OEQ Item 5 at first week of treatment - During the past week, you were satisfied with how quickly you felt your study medication began to work.", "timeFrame": "1 week"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* African American (self-reported)\n* Documented clinical diagnosis of asthma as defined by the American Thoracic Society (ATS) for at least 6 months prior to Visit 2 and be in stable condition.\n* FEV1, measured \u22656 hours after the last dose of short-acting \u03b22-agonist and at least 48 hours after LABA, of 45%-85%, inclusive, of predicted normal.\n\nExclusion Criteria:\n\n* Has been hospitalized at least once for an asthma related condition during the 6 months prior to Visit 2, or has required emergency treatment due to an asthma related condition more than once in the 3 months prior to Visit 2.\n* Has required treatment with systemic corticosteroids (eg, oral, parenteral, ocular, or rectal) for any reason within the 30 days prior to Visit 2.\n* Has a respiratory infection or other viral/bacterial illness, or is recovering from such an illness at the time of Visit 3 that, in the Investigator's opinion, will interfere with the subject's lung function and/or ability to perform spirometry", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Ubaldo Martin, MD", "affiliation": "AstraZeneca", "role": "STUDY_DIRECTOR"}, {"name": "Tomas LG Andersson", "affiliation": "AstraZeneca", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Pell City", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 33.58621, "lon": -86.28609}}, {"facility": "Research Site", "city": "Bentonville", "state": "Arkansas", "country": "United States", "geoPoint": {"lat": 36.37285, "lon": -94.20882}}, {"facility": "Research Site", "city": "Hot Springs", "state": "Arkansas", "country": "United States", "geoPoint": {"lat": 34.5037, "lon": -93.05518}}, {"facility": "Research Site", "city": "Little Rock", "state": "Arkansas", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Research Site", "city": "Malvern", "state": "Arkansas", "country": "United States", "geoPoint": {"lat": 34.36231, "lon": -92.81295}}, {"facility": "Research Site", "city": "Huntington Park", "state": "California", "country": "United States", "geoPoint": {"lat": 33.98168, "lon": -118.22507}}, {"facility": "Research Site", "city": "Long Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "Research Site", "city": "Los Angeles", "state": "California", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Research Site", "city": "Los Angles", "state": "California", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Research Site", "city": "Orange", "state": "California", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -117.85311}}, {"facility": "Research Site", "city": "Rolling Hills Estates", "state": "California", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "Research Site", "city": "Centennial", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.57916, "lon": -104.87692}}, {"facility": "Research Site", "city": "Colorado Springs", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Research Site", "city": "Waterbury", "state": "Connecticut", "country": "United States", "geoPoint": {"lat": 41.55815, "lon": -73.0515}}, {"facility": "Research Site", "city": "Inverness", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.83582, "lon": -82.33037}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Ocala", "state": "Florida", "country": "United States", "geoPoint": {"lat": 29.1872, "lon": -82.14009}}, {"facility": "Research Site", "city": "Tallahassee", "state": "Florida", "country": "United States", "geoPoint": {"lat": 30.43826, "lon": -84.28073}}, {"facility": "Research Site", "city": "Tampa", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Research Site", "city": "Alpharetta", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 34.07538, "lon": -84.29409}}, {"facility": "Research Site", "city": "Atlanta", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Research Site", "city": "Decatur", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.77483, "lon": -84.29631}}, {"facility": "Research Site", "city": "Lawrenceville", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.95621, "lon": -83.98796}}, {"facility": "Research Site", "city": "Lithia Springs", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.794, "lon": -84.66049}}, {"facility": "Research Site", "city": "Lovejoy", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.43622, "lon": -84.31437}}, {"facility": "Research Site", "city": "Chicago", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Research Site", "city": "Hagerstown", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.64176, "lon": -77.71999}}, {"facility": "Research Site", "city": "Lanham", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 38.96875, "lon": -76.8634}}, {"facility": "Research Site", "city": "Largo", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 38.89761, "lon": -76.83025}}, {"facility": "Research Site", "city": "Towson", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.4015, "lon": -76.60191}}, {"facility": "Research Site", "city": "Flint", "state": "Michigan", "country": "United States", "geoPoint": {"lat": 43.01253, "lon": -83.68746}}, {"facility": "Research Site", "city": "Kansas City", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"facility": "Research Site", "city": "St. Louis", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Research Site", "city": "Las Vegas", "state": "Nevada", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Research Site", "city": "Skillman", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 40.42011, "lon": -74.7146}}, {"facility": "Research Site", "city": "New York", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Research Site", "city": "North Syracuse", "state": "New York", "country": "United States", "geoPoint": {"lat": 43.13479, "lon": -76.12992}}, {"facility": "Research Site", "city": "Durham", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "Research Site", "city": "Greenville", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.61266, "lon": -77.36635}}, {"facility": "Research Site", "city": "Raleigh", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Research Site", "city": "Portland", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Research Site", "city": "Blue Bell", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.15233, "lon": -75.26629}}, {"facility": "Research Site", "city": "Charleston", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Research Site", "city": "Spartanburg", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Research Site", "city": "Memphis", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 35.14953, "lon": -90.04898}}, {"facility": "Research Site", "city": "Arlington", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.73569, "lon": -97.10807}}, {"facility": "Research Site", "city": "Dallas", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Research Site", "city": "Fort Worth", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.72541, "lon": -97.32085}}, {"facility": "Research Site", "city": "Ft. Worth", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.72541, "lon": -97.32085}}, {"facility": "Research Site", "city": "Houston", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Research Site", "city": "McKinney", "state": "Texas", "country": "United States", "geoPoint": {"lat": 33.19762, "lon": -96.61527}}, {"facility": "Research Site", "city": "Plano", "state": "Texas", "country": "United States", "geoPoint": {"lat": 33.01984, "lon": -96.69889}}, {"facility": "Research Site", "city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Research Site", "city": "Waco", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.54933, "lon": -97.14667}}, {"facility": "Research Site", "city": "Emporia", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 36.68598, "lon": -77.54248}}, {"facility": "Research Site", "city": "Richmond", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "Research Site", "city": "Virginia Beach", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 36.85293, "lon": -75.97799}}, {"facility": "Research Site", "city": "Milwaukee", "state": "Wisconsin", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}]}, "referencesModule": {"references": [{"pmid": "22329608", "type": "DERIVED", "citation": "Murphy KR, Uryniak T, Martin UJ, Zangrilli J. The effect of budesonide/formoterol pressurized metered-dose inhaler on predefined criteria for worsening asthma in four different patient populations with asthma. Drugs R D. 2012 Mar 1;12(1):9-14. doi: 10.2165/11630600-000000000-00000. Erratum In: Drugs R D. 2012 Mar 1;12(1):15."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "10 subjects were excluded from the FAS: 9 who received the incorrect study medication and 1 who was randomized to receive SYMBICORT pMDI, but never received study medication.\n\nTherefore, 153 subjects (from 156 randomized to Symbicort) and 148 (from 155 randomized to Budesonide) were included in the FAS used to present baseline characteristics.", "recruitmentDetails": "First participant enrolled on 05 June 2008, last participant last visit on 10 September 2009.", "groups": [{"id": "FG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "FG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Randomized", "numSubjects": "156"}, {"groupId": "FG001", "comment": "Randomized", "numSubjects": "155"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Completed participants based on randomized population (156) minus discontinued participants (38).", "numSubjects": "118"}, {"groupId": "FG001", "comment": "Completed participants based on randomized population (155) minus discontinued participants (53).", "numSubjects": "102"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "38"}, {"groupId": "FG001", "numSubjects": "53"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Incorrect enrollment", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Developed study discontinuation criteria", "reasons": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "28"}]}, {"type": "Severe noncompliance to protocol", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Termination due to lab results", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Didn't follow study medication dosage", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Incorrectly Discontinued", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "BG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "153"}, {"groupId": "BG001", "value": "148"}, {"groupId": "BG002", "value": "301"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "38.6", "spread": "13.8"}, {"groupId": "BG001", "value": "39.8", "spread": "15.4"}, {"groupId": "BG002", "value": "39.2", "spread": "14.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "109"}, {"groupId": "BG001", "value": "87"}, {"groupId": "BG002", "value": "196"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "61"}, {"groupId": "BG002", "value": "105"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) Averaged Over Treatment Period", "description": "Mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "populationDescription": "Full analysis set (FAS) was performed and was based on data from all subjects who were randomized, took at least 1 dose of study medication, and contributed sufficient data for calculation of this outcome Measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "143"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.16", "spread": "0.31"}, {"groupId": "OG001", "value": "0.07", "spread": "0.26"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Morning Peak Expiratory Flow (AM PEF) Averaged Over the Treatment Period", "description": "Mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "populationDescription": "Full analysis set (FAS) was performed and was based on data from all subjects who were randomized, took at least 1 dose of study medication, and contributed sufficient data for calculation of this outcome Measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters/minute", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "139"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "25.34", "spread": "43.70"}, {"groupId": "OG001", "value": "7.53", "spread": "32.41"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Evening Peak Expiratory Flow (PM PEF) Averaged Over the Treatment Period", "description": "Mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "populationDescription": "Full analysis set (FAS) was performed and was based on data from all subjects who were randomized, took at least 1 dose of study medication, and contributed sufficient data for calculation of this outcome Measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters/minute", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "141"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "21.61", "spread": "40.75"}, {"groupId": "OG001", "value": "7.67", "spread": "48.97"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Pre-dose Forced Vital Capacity (FVC) Averaged Over the Treatment Period", "description": "Mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "populationDescription": "Full analysis set (FAS) was performed and was based on data from all subjects who were randomized, took at least 1 dose of study medication, and contributed sufficient data for calculation of this outcome Measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "143"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.14", "spread": "0.32"}, {"groupId": "OG001", "value": "0.07", "spread": "0.27"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Pre-dose Forced Expiratory Flow (FEF 25-75%) Averaged Over the Treatment Period", "description": "Mean change of the FEF (25-75%) value at the baseline (Visit 3) compared to average value of the FEF (25-75%) recorded at visits during treatment period (to week 12). The mean change was calculated.", "populationDescription": "Full analysis set (FAS) was performed and was based on data from all subjects who were randomized, took at least 1 dose of study medication, and contributed sufficient data for calculation of this outcome Measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters/second", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "143"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.21", "spread": "0.47"}, {"groupId": "OG001", "value": "0.12", "spread": "0.47"}]}]}]}, {"type": "SECONDARY", "title": "Number of First Predefined Asthma Events by Inhaled Corticosteroid (ICS) Dose at Entry", "description": "Total number of participants with any first predefined asthma event (decrease in FEV1 \u2265 20%,or to \\<40% of predicted normal value,12 puffs of albuterol pMDI per day on 3 or more days, decrease in morning PEF \u2265 20% on 3 or more days, use of rescue medication for 2 or more nights, emergency treatment, hospitalization, use of other asthma medication)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "148"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "67"}]}]}]}, {"type": "SECONDARY", "title": "Number of Withdrawals Due to a Predefined Asthma Event", "description": "Total number of participants who withdrew due to a predefined asthma event (decrease in FEV1 \u2265 20%,or to \\<40% of predicted normal value,12 puffs of albuterol pMDI per day on 3 or more days, decrease in morning PEF \u2265 20% on 3 or more days, use of rescue medication for 2 or more nights, emergency treatment, hospitalization, use of other asthma meds)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "148"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "28"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Total Average Daily Asthma Symptom Score Averaged Over the Treatment Period", "description": "Diary assessment of total asthma symptoms score (treatment average) by Inhaled Corticosteroid (ICS) dose at entry. Asthma symptoms are cough, wheeze and shortness of breath. Each symptom is usually rated from 0-3: 0-no symptoms, 1-mild, 2-moderate and 3-severe. Change from baseline (Visit 3) mean value to average value recorded at visits during treatment period", "populationDescription": "Full analysis set (FAS) was performed and was based on data from all subjects who were randomized, took at least 1 dose of study medication, and contributed sufficient data for calculation of this outcome Measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "142"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.35", "spread": "0.42"}, {"groupId": "OG001", "value": "-0.23", "spread": "0.40"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Nighttime Asthma Symptom Score Averaged Over the Treatment Period", "description": "Diary assessment of nighttime asthma symptoms score (treatment average) by ICS dose at entry. Asthma symptoms are cough, wheeze and shortness of breath. Each symptom is usually rated from 0-3: 0-no symptoms, 1-mild, 2-moderate and 3-severe. Change from baseline (Visit 3) mean value to average value recorded at visits during treatment period; full analysis set (FAS)", "populationDescription": "Full analysis set (FAS) was performed and was based on data from all subjects who were randomized, took at least 1 dose of study medication, and contributed sufficient data for calculation of this outcome Measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "146"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.38", "spread": "0.47"}, {"groupId": "OG001", "value": "-0.26", "spread": "0.42"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Daytime Asthma Symptom Score Averaged Over the Treatment Period", "description": "Diary assessment of daytime asthma symptoms score (treatment average) by ICS dose at entry. Asthma symptoms are cough, wheeze and shortness of breath. Each symptom is usually rated from 0-3: 0-no symptoms, 1-mild, 2-moderate and 3-severe. Change from baseline (Visit 3) mean value to average value recorded at visits during treatment period; full analysis set (FAS)", "populationDescription": "Full analysis set (FAS) was performed and was based on data from all subjects who were randomized, took at least 1 dose of study medication, and contributed sufficient data for calculation of this outcome Measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "143"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.33", "spread": "0.45"}, {"groupId": "OG001", "value": "-0.24", "spread": "0.45"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Awakening-free Nights Averaged Over the Treatment Period", "description": "Diary assessment of number of nights free from awakenings due to asthma; mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "populationDescription": "Full analysis set (FAS) was performed and was based on data from all subjects who were randomized, took at least 1 dose of study medication, and contributed sufficient data for calculation of this outcome Measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Number of nights", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "143"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "17.51", "spread": "26.51"}, {"groupId": "OG001", "value": "11.85", "spread": "25.92"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to the Average in Total Rescue Medication Use Averaged Over the Treatment Period", "description": "Diary assessment of total daily puffs of rescue medication used for asthma symptoms relief; mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "populationDescription": "Full analysis set (FAS) was performed and was based on data from all subjects who were randomized, took at least 1 dose of study medication, and contributed sufficient data for calculation of this outcome Measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Puffs/day", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "144"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.27", "spread": "1.81"}, {"groupId": "OG001", "value": "-0.62", "spread": "1.68"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to the Average in Nighttime Rescue Medication Use Averaged Over the Treatment Period", "description": "Diary assessment of total nighttime puffs of rescue medication used for asthma symptoms relief; mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "populationDescription": "Full analysis set (FAS) was performed and was based on data from all subjects who were randomized, took at least 1 dose of study medication, and contributed sufficient data for calculation of this outcome Measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Puffs/day", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "144"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.79", "spread": "1.07"}, {"groupId": "OG001", "value": "-0.35", "spread": "0.93"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to the Average in Daytime Medication Use Averaged Over the Treatment Period", "description": "Diary assessment of total daytime puffs of rescue medication used for asthma symptoms relief; mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "populationDescription": "Full analysis set (FAS) was performed and was based on data from all subjects who were randomized, took at least 1 dose of study medication, and contributed sufficient data for calculation of this outcome Measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Puffs/day", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "144"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.48", "spread": "0.93"}, {"groupId": "OG001", "value": "-0.27", "spread": "0.92"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to the Average in Rescue Medication-free Days Averaged Over the Treatment Period", "description": "Diary assessment of total (percent) days free from rescue medication use for asthma symptoms relief; mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "populationDescription": "Full analysis set (FAS) was performed and was based on data from all subjects who were randomized, took at least 1 dose of study medication, and contributed sufficient data for calculation of this outcome Measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of days", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "144"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "29.31", "spread": "34.13"}, {"groupId": "OG001", "value": "17.70", "spread": "35.39"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Symptom-free Days Averaged Over the Treatment Period", "description": "Diary assessment of number (percent) of days free from asthma symptoms by ICS dose at entry; mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "populationDescription": "Full analysis set (FAS) was performed and was based on data from all subjects who were randomized, took at least 1 dose of study medication, and contributed sufficient data for calculation of this outcome Measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of days", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "146"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "23.99", "spread": "29.82"}, {"groupId": "OG001", "value": "17.55", "spread": "28.58"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to the Average for Asthma-control Days Averaged Over the Treatment Period", "description": "Diary assessment of number (percent) of asthma-control days (defined as days that were free of symptoms and nighttime and daytime rescue medication use); mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "populationDescription": "Full analysis set (FAS) was performed and was based on data from all subjects who were randomized, took at least 1 dose of study medication, and contributed sufficient data for calculation of this outcome Measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of days", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "147"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "21.89", "spread": "29.48"}, {"groupId": "OG001", "value": "15.12", "spread": "26.80"}]}]}]}, {"type": "SECONDARY", "title": "Perception of Onset of Medication Effect at Last Week of Treatment Assessed by Number of Participants Who Agreed With Item 2 on the Onset of Effect Questionnaire (OEQ)", "description": "Diary assessment of participants age 12 years and older and 18 years and older who agreed with OEQ Item 2 at last week of treatment - During the past week, you could feel your medication begin to work right away", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "12 week", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "144"}, {"groupId": "OG001", "value": "136"}]}], "classes": [{"title": "12 years and older", "categories": [{"measurements": [{"groupId": "OG000", "value": "123"}, {"groupId": "OG001", "value": "112"}]}]}, {"title": "18 years and older", "categories": [{"measurements": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "95"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to End of Treatment in Overall Score on the Asthma Quality of Life Questionnaire-Standardized (AQLQ[S])", "description": "Mean change in overall score at end of treatment for participants age 17 years and older (scores ranged from 1 to 7, with higher scores indicating better quality of life); mean change from baseline (Visit 3) value to average value recorded at visits during treatment period", "populationDescription": "Full analysis set (FAS) was performed and was based on data from all subjects who were randomized, took at least 1 dose of study medication, and contributed sufficient data for calculation of this outcome Measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "125"}, {"groupId": "OG001", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.55", "spread": "0.96"}, {"groupId": "OG001", "value": "0.33", "spread": "1.07"}]}]}]}, {"type": "SECONDARY", "title": "Proportion of Participants Who Reported on the Asthma Control Test (ACT) That Their Asthma Was Controlled at the Last Week of Treatment", "description": "There are 5 questions in the survey, and each question has 5 responses (total score for each question can range from 1 to 5). To score the survey, responses to the 5 questions are added to yield a total score that ranges from 5 (poor control of asthma control) to 25 (complete control of asthma). Score of 20 or higher was indicative of well-controlled asthma.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Proportion of Participants", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "143"}, {"groupId": "OG001", "value": "139"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.524"}, {"groupId": "OG001", "value": "0.518"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Last Week of Treatment in Scores on the Asthma Impact Survey (AIS)", "description": "There are 6 questions in the survey, and each question has 5 responses (total score for each question can range from 6 to 13). Responses to the 6 questions were added to yield a total score that ranged from 36 to 78. Scoring is based on a norm-based method. Higher AIS scores indicated more asthma impact and poorer quality of life; mean change from baseline (Visit 3) value to average value recorded at visits during treatment period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "124"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.05", "spread": "6.79"}, {"groupId": "OG001", "value": "-2.72", "spread": "9.75"}]}]}]}, {"type": "SECONDARY", "title": "Perception of Onset of Medication Effect at Last Week of Treatment Assessed by Number of Participants Who Agreed With Item 5 on the Onset of Effect Questionnaire (OEQ)", "description": "Diary assessment of participants age 12 years and older and 18 years and older who agreed with OEQ Item 5 at last week of treatment - During the past week, you were satisfied with how quickly you felt your study medication began to work.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "12 week", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "144"}, {"groupId": "OG001", "value": "136"}]}], "classes": [{"title": "12 years and older", "categories": [{"measurements": [{"groupId": "OG000", "value": "112"}, {"groupId": "OG001", "value": "99"}]}]}, {"title": "18 years and older", "categories": [{"measurements": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "81"}]}]}]}, {"type": "SECONDARY", "title": "Perception of Onset of Medication Effect at First Week of Treatment Assessed by Number of Participants Who Agreed With Item 2 on the Onset of Effect Questionnaire (OEQ)", "description": "Diary assessment of participants age 12 years and older and 18 years and older who agreed with OEQ Item 2 at first week of treatment - During the past week, you could feel your medication begin to work right away", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "1 week", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "256"}, {"groupId": "OG001", "value": "234"}]}], "classes": [{"title": "12 years and older", "categories": [{"measurements": [{"groupId": "OG000", "value": "113"}, {"groupId": "OG001", "value": "95"}]}]}, {"title": "18 years and older", "categories": [{"measurements": [{"groupId": "OG000", "value": "101"}, {"groupId": "OG001", "value": "81"}]}]}]}, {"type": "SECONDARY", "title": "Perception of Onset of Medication Effect at First Week of Treatment Assessed by Number of Participants Who Agreed With Item 5 on the Onset of Effect Questionnaire (OEQ)", "description": "Diary assessment of participants age 12 years and older and 18 years and older who agreed with OEQ Item 5 at first week of treatment - During the past week, you were satisfied with how quickly you felt your study medication began to work.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "1 week", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily."}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "256"}, {"groupId": "OG001", "value": "234"}]}], "classes": [{"title": "12 years and older", "categories": [{"measurements": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "83"}]}]}, {"title": "18 years and older", "categories": [{"measurements": [{"groupId": "OG000", "value": "86"}, {"groupId": "OG001", "value": "70"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Symbicort", "description": "Symbicort pressurized metered dose inhaler (pMDI) 160/4.5 mcg x 2 actuations, twice daily.", "seriousNumAffected": 1, "seriousNumAtRisk": 156, "otherNumAffected": 18, "otherNumAtRisk": 156}, {"id": "EG001", "title": "Budesonide", "description": "Budesonide inhalation dry powder inhaler (DPI) 180 mcg x 2 inhalations, twice daily.", "seriousNumAffected": 2, "seriousNumAtRisk": 155, "otherNumAffected": 12, "otherNumAtRisk": 155}], "seriousEvents": [{"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 155}]}, {"term": "Ovarian Cyst Ruptured", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 155}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 155}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 155}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 155}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "If Sponsor does not publish within 2 years after study completion, PI is permitted to publish, with confidential information removed from manuscript. Sponsor will have opportunity to review and approve publication at least 60 days pior to being submitted/disclosed. Sponsor can request, in writing, an additional 90 day embargo."}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "aztrial_results_posting@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019819", "term": "Budesonide"}, {"id": "D000068759", "term": "Formoterol Fumarate"}, {"id": "D000069502", "term": "Budesonide, Formoterol Fumarate Drug Combination"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Of 1", "relevance": "HIGH"}, {"id": "M304", "name": "Formoterol Fumarate", "asFound": "Channel", "relevance": "HIGH"}, {"id": "M452", "name": "Budesonide, Formoterol Fumarate Drug Combination", "asFound": "Early Stage", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}